Concerns Grow Over Safety of Aduhelm After Death of Patient Who Got the Drugnews2021-11-22T16:00:09+00:00November 22nd, 2021|The New York Times|
Biogen’s Alzheimer’s drug is unlikely to win E.U. approval.news2021-11-18T04:32:41+00:00November 18th, 2021|The New York Times|
Sales of Biogen’s Alzheimer’s Drug Fall Short of Expectationsnews2021-10-20T20:06:11+00:00October 20th, 2021|The New York Times|
House Committees Demand F.D.A. Records on Alzheimer’s Drug Approvalnews2021-09-02T17:20:46+00:00September 2nd, 2021|The New York Times|
Biogen’s Aduhelm Sales Total $2 Million in Second Quarternews2021-07-22T21:10:02+00:00July 22nd, 2021|The New York Times|
How an Unproven Alzheimer’s Drug Got Approvednews2021-07-20T02:12:00+00:00July 20th, 2021|The New York Times|
Ohio Clinic Says It Won’t Administer Alzheimer’s Drug to Patientsnews2021-07-15T03:11:54+00:00July 15th, 2021|The New York Times|
F.D.A. Seeks Investigation of Its Own Alzheimer’s Drug Approvalnews2021-07-09T20:13:30+00:00July 9th, 2021|The New York Times|
In Reversal, F.D.A. Calls for Limits on Who Gets Alzheimer’s Drugnews2021-07-09T19:12:53+00:00July 9th, 2021|The New York Times|
